Trials / Completed
CompletedNCT01361412
Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy
An Optional Research Study to Identify Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy in Subjects Already Enrolled in Clinical Study TR002
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Circassia Limited · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to identify changes in potential biomarkers after peptide immunotherapy for that may subsequently be developed as biomarkers that correlate with clinical efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ToleroMune Ragweed | Intradermal administration 1x8 administrations, 2 weeks apart |
| BIOLOGICAL | Placebo | Intradermal injection 1x8 administrations, 2 weeks apart |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2011-05-26
- Last updated
- 2011-10-07
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01361412. Inclusion in this directory is not an endorsement.